Literature DB >> 15010701

Founder mutations among the Dutch.

Maurice P A Zeegers1, Frans van Poppel, Robert Vlietinck, Liesbeth Spruijt, Harry Ostrer.   

Abstract

Many genetic disorders demonstrate mutations that can be traced to a founder, sometimes a person who can be identified. These founder mutations have generated considerable interest, because they facilitate studies of prevalence and penetrance and can be used to quantify the degree of homogeneity within a population. This paper reports on founder mutations among the Dutch and relates their occurrence to the history and demography of the Netherlands. International migration, regional and religious endogamy, and rapid population growth played key roles in shaping the Dutch population. In the first millenniums BC and AD, the Netherlands were invaded by Celts, Romans, Huns, and Germans. In more recent times, large numbers of Huguenots and Germans migrated into the Netherlands. Population growth within the Netherlands was slow until the 19th century, when a period of rapid population growth started. Today, the Dutch population numbers 16 million inhabitants. Several different classes of founder mutations have been identified among the Dutch. Some mutations occur among people who represent genetic isolates within this country. These include mutations for benign familial cholestasis, diabetes mellitus, type I, infantile neuronal ceroid lipofuscinosis, L-DOPA responsive dystonia, and triphalangeal thumb. Although not related to a specific isolate, other founder mutations were identified only within the Netherlands, including those predisposing for hereditary breast-ovarian cancer, familial hypercholesterolemia, frontotemporal dementia, hereditary paragangliomas, juvenile neuronal ceroid lipofuscinosis, malignant melanoma, protein C deficiency, and San Filippo disease. Many of these show a regional distribution, suggesting dissemination from a founder. Some mutations that occur among the Dutch are shared with other European populations and others have been transmitted by Dutch émigrés to their descendents in North America and South Africa. The occurrence of short chromosomal regions that have remained identical by descent has resulted in relatively limited genetic heterogeneity for many genetic conditions among the Dutch. These observations demonstrate the opportunity for gene discovery for other diseases and traits in the Netherlands.

Entities:  

Mesh:

Year:  2004        PMID: 15010701     DOI: 10.1038/sj.ejhg.5201151

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

1.  New contributions to the study of common double mutants in the human LDL receptor gene.

Authors:  M Teresa Tejedor; Ana Cenarro; Diego Tejedor; Marianne Stef; Lourdes Palacios; Isabel de Castro; Angel L García-Otín; Luis V Monteagudo; Fernando Civeira; Miguel Pocovi
Journal:  Naturwissenschaften       Date:  2011-09-21

2.  Recurrent and founder mutations in inherited cardiac diseases in the Netherlands.

Authors:  J P van Tintelen; A A M Wilde; J D H Jongbloed
Journal:  Neth Heart J       Date:  2009-11       Impact factor: 2.380

Review 3.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

4.  No evidence for increased mortality in SDHD variant carriers compared with the general population.

Authors:  Leonie T van Hulsteijn; Berdine Heesterman; Jeroen C Jansen; Jean-Pierre Bayley; Frederik J Hes; Eleonora P M Corssmit; Olaf M Dekkers
Journal:  Eur J Hum Genet       Date:  2015-03-11       Impact factor: 4.246

5.  Loss of LMOD1 impairs smooth muscle cytocontractility and causes megacystis microcolon intestinal hypoperistalsis syndrome in humans and mice.

Authors:  Danny Halim; Michael P Wilson; Daniel Oliver; Erwin Brosens; Joke B G M Verheij; Yu Han; Vivek Nanda; Qing Lyu; Michael Doukas; Hans Stoop; Rutger W W Brouwer; Wilfred F J van IJcken; Orazio J Slivano; Alan J Burns; Christine K Christie; Karen L de Mesy Bentley; Alice S Brooks; Dick Tibboel; Suowen Xu; Zheng Gen Jin; Tono Djuwantono; Wei Yan; Maria M Alves; Robert M W Hofstra; Joseph M Miano
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-14       Impact factor: 11.205

6.  Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant.

Authors:  Maurice P Zeegers; Humera S Khan; Leo J Schouten; Boukje A C van Dijk; R Alexandra Goldbohm; Jack Schalken; Shahin Shajahan; Alexander Pearlman; Carole Oddoux; Piet A van den Brandt; Harry Ostrer
Journal:  Eur J Hum Genet       Date:  2010-08-11       Impact factor: 4.246

7.  The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family.

Authors:  Erik F Hensen; Jeroen C Jansen; Maaike D Siemers; Jan C Oosterwijk; Annette Hjt Vriends; Eleonora Pm Corssmit; Jean-Pierre Bayley; Andel Gl van der Mey; Cees J Cornelisse; Peter Devilee
Journal:  Eur J Hum Genet       Date:  2010-01       Impact factor: 4.246

Review 8.  Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.

Authors:  Carlos Andrés Ossa; Diana Torres
Journal:  Oncologist       Date:  2016-06-10

9.  Unexpected occurrence of xeroderma pigmentosum in an uncle and nephew.

Authors:  Stéphanie Christen-Zaech; Kyoko Imoto; Sikandar G Khan; Kyu-Seon Oh; Deborah Tamura; John J Digiovanna; Jennifer Boyle; Nickolas J Patronas; Raphael Schiffmann; Kenneth H Kraemer; Amy S Paller
Journal:  Arch Dermatol       Date:  2009-11

10.  A 475 years-old founder effect involving IL12RB1: a highly prevalent mutation conferring Mendelian Susceptibility to Mycobacterial Diseases in European descendants.

Authors:  J Yancoski; C Rocco; A Bernasconi; M Oleastro; L Bezrodnik; C Vrátnica; F Haerynck; S D Rosenzweig
Journal:  Infect Genet Evol       Date:  2009-03-09       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.